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 Gastric cancer (GC) is predominantly a disease of the elderly as approximately 60% of all patients are 70 years of age or 
older. At present, there are no guidelines dedicated to this group, and current treatment strategies are mainly based on 
evidence from clinical trials often carried out on younger patients. 
 The GC in older patients is typically located in the distal third of the stomach and it is well/moderately differentiated, having 
mainly an intestinal type of tumor by Lauren’s criteria. Lymph nodes and peritoneal metastases have been reported less 
frequently in comparison to younger patients. 
 Older patients are a very heterogeneous population in terms of co-morbidity, physical reserve, cognitive function, and 
social support. Treatment side effects can cause more serious problems than cancer itself, so the comprehensive geriatric 
assessment (CGA) is as important as the cancer staging. Chronological age alone is not a contraindication for treatment. 
Surgery is the preferred standard treatment option for resectable GC. However, the prognostic significance of surgery and 
other treatment options is unknown in the frail group. Fitter patients, according to the CGA, should qualify for the same 
treatment as younger patients. Frail patients should be discussed during oncogeriatric meetings. Surgery, the benefits 
of limitation of the surgical resection, and no or non-selective lymphadenectomy should all be analyzed. In experienced 
hands, minimal invasive surgery is favorable in the short- and long-term. In cases of severe frailty, the best supportive care 
can often be the best option. 
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The prevalence of gastric cancer (GC) has gradually decreased 
over the last decades, nevertheless, it remains a major cause 
of cancer-related death and remains the fifth most common 
cancer in the world. GC is also predominantly a disease of 
the elderly as approximately 60% of all patients are 70 years 
and older. Subsequently, an aging population means that the 
number of older patients with GC is increasing continuously [1].
Surgery is the preferred standard treatment option for 
resectable GC. However, the prognostic significance of surgery 
and other treatment modalities is still unknown in frail patients. 
At present, there are also no guidelines dedicated to older 
patients and current treatment strategies are mainly based on 
evidence from clinical trials frequently carried out on younger 
patients [2]. Therefore, surgeons and oncologists experience 
many difficulties when making decision in this age group. Very 
often these decisions are taken based on comorbidity burden, 
subjective assessments or are age driven. 
The clinical and pathological characteristics of 
GC in older patients
There is a male predominance among older patient with GC, 
which contrasts with younger patients where the gender ratio 
is typically closer to 1:1. There is usually no family history. The 
GC is typically located in the distal third of the stomach and it is 
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well/moderately differentiated. Moreover, histologically, older 
patients present mainly with an intestinal type of tumor by 
Lauren’s criteria. It frequently metastasizes to the liver. Lymph 
nodes and peritoneal metastases have been reported less 
frequently in comparison to younger patients [3]. 
According to the Japanese classification of GC, the predo-
minant type of early gastric cancer (EGC) in older patients is 
the superficial depressed type IIc, followed by the superficial 
elevated type IIa, and the polypoid type I [4]. Genetically, older 
patients have more frequent TP-53 and HER2 overexpression, 
and more microsatellite instability-high tumors [5].
Preoperative assessment and treatment 
decisions
As was mentioned in our previous publications, the population 
of older patients is very heterogeneous in terms of co-morbi-
dity, physical reserve, cognitive function, and social support 
[6]. Current routine pre-operative assessment also cannot ade-
quately identify patients at risk. Therefore, the comprehensive 
geriatric assessment (CGA) was introduced to help determine 
the primary status of the older patient, to diagnose frailty syn-
drome (surrogate of the biological age), and to identify how to 
optimize the patient’s condition before the start of the treat-
ment. Many older adults have unidentified, uncommunicated, 
and therefore unaddressed aging-related conditions that are 
associated with morbidity and early mortality [7, 8]. The natural 
life expectancy of older people is surely shorter than that of 
younger people. Considering their limited remaining lifetime, 
their postoperative quality of life is as valuable as the need to 
cure or remove the cancer. Therefore, the International Soci-
ety of Geriatric Oncology (SIOG) and The European Society 
for Medical Oncology (ESMO) recommends the use of the 
CGA to determine biological age before the beginning of the 
treatment.
In general, based on the CGA, we can differentiate three 
groups of older patients: 
1. Fit: patients without any deficits in the CGA domains and 
less than 80 years old. In this group, standard oncologic 
treatment can be offered and the postoperative outcomes 
are comparable with younger patients.
2. Pre-frail: patients with one or two deficits in the CGA do-
mains or more than 80 years old. In these patients, rehabi-
litation should be recommended to improve resilience to 
surgical stress by, at least, augmenting functional capacity 
and nutritional status before surgery.
3. Frail patients: patients with three or more impaired do-
mains in the CGA or 80 years old with two deficits in the 
CGA. A tailored approach should be discussed in a geriatric 
multidisciplinary team meeting [9].
It is also possible to determine the severity of the frailty 
using a cumulative deficit model for the CGA [10]. 
Treatment of gastric cancer in older patients
The therapeutic options for GC depending on the cancer 
stage [11, 12] including options for frailer, older patients, are 
presented in table I. 
Patients with early GC (T1) can undergo endoscopic re-
section using an endoscopic submucosal dissection (ESD) 
technique. The ESD, in experienced hands, is an effective and 
safe procedure for older patients, with clinical and oncological 
outcomes comparable to younger population. A higher preva-
lence of cardiopulmonary problems was reported during the 
procedure when compared to the younger group. However, 
they were managed effectively during the procedure without 
further clinical sequelae. Therefore, the ESD should be the 
standard treatment for management of early GC fulfilling the 
Japanese criteria of a negligible risk of lymph node metastasis 
for both fit and frail patients [13, 14].
At present, surgical resection is the main curative treatment 
option for patients with gastric cancer GC stage T1b and higher. 
However, it can cause high morbidity and mortality, particularly 
in the older population. Improvement in anesthesiology, stan-
dardization of the surgical technique, and perioperative care 
improve the 30-day outcomes significantly in comparison to 
previously reported data. Katai et al. and Zhou et al. reported 
that surgery can be safely performed with an excellent pro-
gnosis in older patients with GC [15, 16]. In contrast, Fujisaki 
et al. observed that after gastrectomy there was as higher 
rate of postoperative non-surgical complications (pneumonia, 
heart failure, and liver dysfunction) in comparison to younger 
patients [17]. In turn, Wakahara et al. observed a 10% increase 
in the overall postoperative morbidity, including the rate of 
anastomotic leakage that was significantly elevated in the older 
group [18]. Mengardo et al. concluded that  ≥80 years of age is 
Table I. Therapeutic options for gastric cancer depending on the cancer stage [11, 12], including options for frail, older patients
Stage factors Fit patients Frail patients 
T1N0 • endoscopic resection
• limited resection
• endoscopic resection
• best supportive care in severe frailty 
T2–4 N0–2 • preoperative chemotherapy, followed by total/subtotal 
gastrectomy and postoperative chemotherapy
• surgery followed by adjuvant chemotherapy
• subtotal/partial gastrectomy with no or selected 
lymphadenectomy
• palliative treatment
• best supportive care in severe frailty
not-resectable metastatic • palliative treatment 
• clinical trials
• best supportive care 
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a negative independent factor impacting overall survival (OS), 
thus, these patients should be carefully selected for surgery 
[19]. Endo et al. reported on a heterogeneous population of 
patients aged 85 years who underwent surgery for gastric 
cancer. This group had a better prognosis than those who did 
not undergo surgery. Females, patients aged 85–89 years, and 
patients with stage IB–IIIC cancer had significantly better OS 
with surgery than without. For males, patients aged 90 years 
of age, or stage IA patients, the decision to perform surgery 
should be carefully discussed, and best support care may be 
an optimal strategy [20]. Most of the postoperative deaths in 
these patients were due to pneumonia and not due to GC. 
However, the most important limitation of the study is that 
the authors divided the patients based on their chronological 
age alone and not on the presence of frailty factors (a sur-
rogate of biological age). Therefore, I would view the group 
of 90-year-old patients in this study as being equivalent to 
a severe frailty group. 
To conclude, it appears that fit and mildly frail patients 
can and should be operated on with acceptable short-term 
outcomes. In the case of severe frailty, surgery might not be 
the optimal option. However, currently studied patients were 
fit older patients mostly defined based on their chronological 
age and/or comorbidity burden and not on the biological age. 
We are still lacking good data on the long-term outcomes of 
frail patients, because their risk of mortality after hospitalization 
remains particularly high during the first 6 months. Moreover, 
surgery is a well-known trigger for postoperative institutiona-
lization and dependency on other people in older patients. 
Therefore, quality of life as an end point is even more important 
than OS or disease-free survival (DFS). 
The next question is the extent of the surgery. Total/subtotal 
gastrectomy with a D2 lymphadenectomy is recommended for 
most fit patients with resectable advanced GC as a standard 
surgical procedure. In the case of older patients, the essential 
clinical question is whether perioperative trauma can be limited 
which, in turn, may reduce the risk of postoperative morbidity/
mortality and increase the quality of life. Therefore, there is 
a trend among surgeons to perform a subtotal gastrectomy, 
since a total gastrectomy in this age group had been associated 
with higher rates of postoperative morbidity and mortality. 
A Dutch study reported that older patients qualified to total ga-
strectomy had a relative risk of 2.15 for in-hospital mortality and 
3.25 for morbidity, as compared to those who had undergone 
a partial gastrectomy [21]. Similarly, Katai et al. demonstrated 
that total gastrectomy in octogenarian patients was associated 
with higher operative and 90-day mortality [22]. Moreover, the 
5-year overall survival was better in older patients in partial as 
opposed to total gastrectomy (86% vs. 67%). There are also 
studies showing the benefit to limit the resection to specific 
margins in the case of cancers with beneficial histology [23].
To conclude, the extent of the resection, if there is any po-
ssibility, should be limited in older patients. However, similarly 
as above, we do not have good studies using biological age 
as opposed to chronological.
Limited data are also available to clarify the survival bene-
fit of D2 lymphadenectomy for older patients. Shinozuka et 
al. analyzed 3484 patients from many centers who received 
surgical resection for GC. The authors selected patients aged 
≥80 years with T2–4 GC. Their performed propensity score 
matching to balance the essential variables (stage of disease 
and gastrectomy type). The D2 group had significantly longer 
operative times, more blood loss, and more retrieved lymph 
nodes than the non-D2 group. The D2 group had a greater 
incidence of intra-abdominal abscesses (grade ≥II in the Cla-
vien–Dindo classification) than the non-D2 group. The overall, 
disease-specific and relapse-free survival rates of the D2 group 
tended to be worse than those of the non-D2 group (hazard 
ratios: 1.49, 1.70 and 1.14, respectively). The non-D2 group had 
a slightly longer relapse-free survival compared with that of 
the D2 group, indicating that limited lymphadenectomy did 
not increase the risk of disease recurrence [24]. 
Also essential, is that postoperative complications after 
gastrectomy influence the prognosis. Wang et al. and Kanda 
et al. showed that morbidity following gastrectomy shortens 
the long-term survival of older patients with GC; D2 lympha-
denectomy was an independent risk factor of postoperative 
complications [25–27]. In turn, Takeda et al. recommend that 
standard radical lymph node dissection should be used for 
tumors extending through the serosa (T3) and/or involving 
extragastric lymph nodes (N2), even in patients aged 80 years 
or more [28]. 
To conclude, it seems that in fit (based on the CGA) older 
patients a standard D2 lymphadenctomy can be carried out. 
However, the more severe the frailty, the more selective the 
lymphadenectomy should be. Larger prospective studies are 
required to clarify the necessity of D2 lymph node dissection 
to treat older, frail patients.
Most of the studies on minimal invasive surgery in older 
patients with the GC report have comparable oncological 
results and good short-/long-term outcomes both in unmat-
ched and propensity-matched patients aged 80 years and 
older [29]. Total gastrectomy, a Charlson comorbidity index 
≥4, and pathological N stage were identified as independent 
prognostic factors for overall survival in patients undergoing 
a laparoscopic gastrectonmy [30]. The first Western experience 
in laparoscopic distal gastrectomy was published by Rausei S. 
et al. this year, including 46 patients aged 80 years and older. 
The authors concluded that the laparoscopic approach redu-
ces the effect of surgical trauma without compromising the 
oncological results [31]. There are also the first studies analyzing 
frailty as a prognostic factor in the laparoscopic group of older 
patients with GC. Tanaka et al. reported that operative com-
plications (especially systemic complications) were positively 
associated with an increase in clinical frailty scores. Moreover, 
the overall 5-year survival rate and the 5-year survival rates 
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must be stressed that, although, there was no upper age limits 
included in the study, the patients were generally fit.  In turn, 
Slagter et al. evaluated treatment-related toxicity, treatment 
compliance, surgical complications, and event-free survival 
in older (>70 years) versus younger (<70 years) patients who 
underwent perioperative treatment for GC. 788 patients with 
resectable gastric cancer were randomized before the start 
of any treatment, and received preoperative chemotherapy 
(3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine), 
followed by surgery, followed by either postoperative chemo-
therapy or chemoradiotherapy (45 Gy, cisplatin, capecitabine). 
During preoperative chemotherapy, 77% of older adults versus 
62% of younger adults experienced severe toxicity (p < 0.001) 
and older adults received significantly lower relative dose 
intensities for all chemotherapeutic drugs. Equal proportions 
of older and younger adults underwent curative surgery (80% 
vs. 81%), with comparable postoperative complications and 
postoperative mortality; 64% of older patients and 78% of 
young patients started adjuvant chemotherapy (p < 0.001). 
There was no difference in the severe toxicity rate between 
the groups; however, older adults received significantly lower 
relative dose intensities for all chemotherapeutic drugs [37]. 
The question as to whether this kind of treatment can be 
proposed to frail patients with good short- and long-term 
outcomes still remains unanswered.  
In the case of patients with resected gastric cancer who 
have not received preoperative chemotherapy, adjuvant che-
motherapy is recommended [38]. However, adjuvant chemo-
therapy is, generally, less well tolerated than preoperative che-
motherapy. Therefore, the latter may be the preferential option. 
An interesting study was published this year by Schendel et 
al. including 75-year and older patients with GC from Canada. 
The 5 year DFS for the surgery only group was 67.3% and for 
the multimodality group was 52.9% (p = 0.25). The 5 year OS 
for the surgery only group was 38.9% and for the multimodality 
group was 47.1% (p = 0.52). The authors concluded that even 
with surgery alone, selected older patients with non-metasta-
tic gastric cancer can obtain prolonged survival, despite not 
receiving standard of care multimodality therapy [39].
Concluding, limited data on these topics are available 
from the Western world. Most of the studies were conducted 
in Asia and the applicability of these results in Europe remains 
uncertain, not to mention the evaluation of frailty based on 
the comprehensive geriatric assessment.
Palliative treatment
Currently, there is little evidence of the role of palliative resection 
in GC in older patients. The REGATTA trial including patients 
with incurable gastric cancer, randomizing them to palliative 
chemotherapy alone or to gastrectomy with chemotherapy, 
showed no survival advantage of surgery, with the median OS 
at 16.6 months (95% CI: 13.7–19.8) with chemotherapy versus 
14.3 months (95% CI: 11.8–16.3) with surgery and chemotherapy. 
for those with a clinical frailty score of 1–2, 3–4, and 5–7 were 
respectively 70.9%, 59.8%, and 35.1%. Therefore, the authors 
conclude that frailty has a great impact on operative morbi-
dity and prognosis in the elderly, and the CFS score could be 
a promising prognostic predictor, especially for frail patients 
with advanced gastric cancer [32].
To conclude, minimal invasive gastrectomy has the po-
tential to provide a balance between oncological clearance 
and quality of life issues that remain crucially important in 
the older population. However, full a comprehensive geriatric 
assessment was not performed in any of the studies. The legal 
point of view is also interesting. Older cancer patients are offe-
red a standardized treatment model geared toward younger 
adults by their physicians, due to the fear of being accused 
of undertaking the incorrect oncological treatment. In this 
context, it may be useful to surgeons to highlight the Polish 
Supreme Court verdict from September 24, 2015 (V CSK 738/14 
– the extent of obligation to provide information by physi-
cians), discussed in the article by dr. Radosław Drozda from 
the Department of Forensic Medicine at the Wroclaw Medical 
University. It concluded that “the choice between alternative 
treatment methods belongs to the patient, and the clinician 
should present the patient with all available treatment options 
that are possible in their physical condition – at most with an 
indication as to which of these options is the most beneficial 
according to the doctor…” and “…it is the patient – despite 
a lack of medical training – who should make the ultimate 
decision on the surgical method that they will be subjected 
to. The role of the physician is to convince the patient why 
(and for what medical reasons) it might be worth undergoing 
a riskier procedure. The patient however has the right (driven 
by personal reasons or even superstition) to pick a method 
that would be less invasive and is likely to have a lower efficacy 
than the method proposed by the clinician” [33].
Perioperative chemotherapy
Due to high recurrence rates, multimodal treatment is a stan-
dard for GC in stage IB disease and higher. However, concerns 
remain regarding chemotherapy in older patients due to the 
risks of perioperative morbidity from toxicity. Therefore, to 
determine the feasibility of treating patients over the age of 
65, a predefined exploratory subgroup analysis of patients 
within the randomized phase II FLOT 65+ trial compared pa-
tients treated with perioperative FLOT (5-fluorouracil, oxali-
platin and docetaxel) or FLO (without docetaxel). In the study, 
a high level of adherence among older patients was observed: 
85% of patients received all 4 preoperative cycles of FLOT, 
and there was no clinically significant increase in grade 3–4 
toxicity postoperatively. Mortality and morbidity rates were 
comparable to other trials,  including patients across all ages. 
The authors concluded that neoadjuvant FLO or FLOT che-
motherapy is therefore a reasonable option in older  patients 
with locally advanced resectable gastric cancer [34–36]. It 
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The included patients were young, between 49 and 67 years old. 
It seems that palliative gastrectomy should not be considered 
in patients with advanced gastric cancer, unless there are other 
indications (bleeding or obstruction) [40]. 
As far as palliative chemotherapy is concerned, in patients 
over 70, it is recommended to consider tailored treatment 
based on biological age with two/three-drug chemotherapy 
regimens and dose reduced therapy. 
Conclusions
Chronological age should not be a contraindication for multi-
modal radical treatment in older patients. The frailty (surrogate 
of the biological age) evaluation should be the basis for the 
discussion on treatment planning. At present, it is one of the 
most reliable factors predicting functional decline in different 
organs, making it more difficult for older patients to overcome 
surgical stress. Moreover, the potential benefits of surgery for 
frail patients with GC must be explored in the context of their 
shorter life expectancy compared to younger patients.
Therefore, before treatment begins, the following qu-
estions should be discussed:
• Is the currently planned treatment strategy correct? Are 
there alternative treatment options? 
• What is the result of the comprehensive geriatric asses-
sment? Can frailty syndrome be diagnosed in the patient? 
• What is the risk of complications? 
• What would the patient’s lifespan be without treatment? 
• What are the goals, preferences, and expectations of the 
patient? What effect might the treatment have on these 
goals? 
• Is it possible to improve the patient’s state prior to the 
surgical procedure? 
Fit patients, according to the comprehensive geriatric 
assessment, should be qualified for the same treatment as 
younger patients. Prefrail patients should undergo pre rehabi-
litation and be reevaluated. Frail patients should be discussed 
in the oncogeriatric meeting. In the case of surgical treatment, 
the limitation of the resection’s extent, no or selective lym-
phadenectomy should be considered. In experienced hands, 
minimal invasive surgery may be beneficial regarding the 
short- and long-term outcome. In the case of severe frailty, best 
supportive treatment can be the optimal option. The goal of 
the modifications is to reduce surgical stress. In older patients 
(aged 75 years or older), the pathological outcome and po-
stoperative complications are predictors of survival, whereas 
pathological outcome and chemotherapy are predictors of 
survival in the younger population (aged 74 years or less). Thus, 
the prevention of postoperative morbidity may contribute to 
improved prognosis for older patients with gastric cancer [41].
However, we still need better designed studies on a larger 
group of patients using frailty evaluation. Existing studies on 
this topic are limited, too small, and lack important details with 
satisfactory statistical clout. In clinical observational studies, 
overall survival is usually considered the gold standard endpo-
int because it is simple and reliable to measure. Overall survival 
could be diluted by non-cancer-related deaths, especially in 
the older population. Therefore, cancer-specific survival and 
relative survival should be used in this group [42, 43]. Moreover, 
novel endpoints should be explored such as patients reported 
outcomes to establish appropriate treatment guidelines for 
frail, older patients.
Conflict of interest: none declared
Jakub Kenig 
Jagiellonian University Medical College
I Chair of General Surgery
Department of General, Oncologic, Gastrointestinal Surgery and 
Transplantology 
 ul. Jakubowskiego 2 
30-688 Kraków, Poland
e-mail: jkenig@cm-uj.krakow.pl
Received: 4 Jul 2021 
Accepted: 6 Jul 2021
References
1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk 
factors and prevention.  Prz Gastroenterol. 2019; 14(1): 26–38, doi: 
10.5114/pg.2018.80001, indexed in Pubmed: 30944675.
2. Gaitonde S, Fischer T, Jones M, et al. Young age, disparities, and survival 
in gastric adenocarcinoma: Implications for screening strategies. J Clin 
Oncol. 2017; 35(4_suppl): 17–17, doi: 10.1200/jco.2017.35.4_suppl.17.
3. Joharatnam-Hogan N, Shiu KK, Khan K. Challenges in the treatment of 
gastric cancer in the older patient. Cancer Treat Rev. 2020; 85: 101980, 
doi: 10.1016/j.ctrv.2020.101980, indexed in Pubmed: 32065879.
4. Fujiya T, Endoh K, Mikuni J, et al. Clinicopathological Characteristics 
and Surgical Outcome of Gastric Carcinoma with Regard to Aging. Jpn 
J Gastroenterol Surg. 1997; 30(7): 1699–1705, doi: 10.5833/jjgs.30.1699.
5. Wu CW, Chen MH, Huang KH, et al. The clinicopathological characteri-
stics and genetic alterations between younger and older gastric cancer 
patients with curative surgery. Aging. 2020; 12(18): 18137–18150, doi: 
10.18632/aging.103627.
6. Kenig J. Oncogeriatrics (part 1.). Frailty in older adults with cancer. 
Nowotwory. Journal of Oncology. 2019; 69(2): 55–57, doi: 10.5603/
njo.2019.0010.
7. Loh KP, Soto-Perez-de-Celis E, Hsu T, et al. What Every Oncologist Sho-
uld Know About Geriatric Assessment for Older Patients With Cancer: 
Young International Society of Geriatric Oncology Position Paper. J 
Oncol Pract. 2018; 14(2): 85–94, doi: 10.1200/JOP.2017.026435, indexed 
in Pubmed: 29436306.
8. Klabunde CN, Ambs A, Keating NL, et al. The role of primary care phy-
sicians in cancer care. J Gen Intern Med. 2009; 24(9): 1029–1036, doi: 
10.1007/s11606-009-1058-x, indexed in Pubmed: 19597893.
9. Grodzicki T, Kenig J. Problemy okołooperacyjne u osób w wieku pode-
szłym. PZWL Wydawnictwo Lekarskie, Warszawa 2018.
10. Kenig J, Szabat K. Oncogeriatrics (part 7.). Geriatric assessment for older 
patients with cancer. Nowotwory. Journal of Oncology. 2020; 70(4): 
153–157, doi: 10.5603/njo.2020.0031.
11. Smyth EC, Verheij M, Allum W, et al. ESMO Guidelines Committee. Gastric 
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol. 2016; 27(suppl 5): v38–v49, doi: 10.1093/annonc/
mdw350, indexed in Pubmed: 27664260.
12. Kulig J, Wallner G, Drews M, et al. Polish Consensus on Treatment of 
Gastric Cancer; update 2017. Pol Przegl Chir. 2017; 89(5): 55–68.
13. Yang TC, Hou MC, Chen PH, et al. Clinical Outcomes and Complications 
of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasms 
in the Elderly. Medicine (Baltimore). 2015; 94(44): e1964, doi: 10.1097/
MD.0000000000001964, indexed in Pubmed: 26554806.
14. Sinagra E, Luppino I, Messina M, et al. Endoscopic approach to early 
gastric cancer in older adults. J Geriatr Oncol. 2021; 12(1): 160–162, doi: 
10.1016/j.jgo.2020.05.005, indexed in Pubmed: 32467026.
250
15. Katai H, Sasako M, Sano T, et al. Gastric cancer surgery in the elderly 
without operative mortality. Surg Oncol. 2004; 13(4): 235–238, doi: 
10.1016/j.suronc.2004.09.007, indexed in Pubmed: 15615661.
16. Zhou CJ, Chen FF, Zhuang CL, et al. Feasibility of radical gastrectomy for 
elderly patients with gastric cancer. Eur J Surg Oncol. 2016; 42(2): 303–
311, doi: 10.1016/j.ejso.2015.11.013, indexed in Pubmed: 26710992.
17. Fujisaki M, Shinohara T, Hanyu N, et al. Laparoscopic gastrectomy for 
gastric cancer in the elderly patients. Surg Endosc. 2016; 30(4): 1380–
1387, doi: 10.1007/s00464-015-4340-5, indexed in Pubmed: 26123337.
18. Nie RC, Chen FP, Yuan SQ, et al. Evaluation of objective response, dise-
ase control and progression-free survival as surrogate end-points for 
overall survival in anti-programmed death-1 and anti-programmed 
death ligand 1 trials. Eur J Cancer. 2019; 106: 1–11, doi: 10.1016/j.
ejca.2018.10.011, indexed in Pubmed: 30453169.
19. Mengardo V, Cormack OMc, Weindelmayer J, et al. Multicenter Study 
of Presentation, Management, and Postoperative and Long-Term 
Outcomes of Septegenerians and Octogenerians Undergoing Gastrec-
tomy for Gastric Cancer. Ann Surg Oncol. 2018; 25(8): 2374–2382, doi: 
10.1245/s10434-018-6543-1, indexed in Pubmed: 29868974.
20. Endo S, Shimizu Y, Ikenaga M, et al. Survival benefit of gastrectomy for 
gastric cancer in patients ≥85  years old: A retrospective propensity 
score-matched analysis. Surgery. 2017; 161(4): 984–994, doi: 10.1016/j.
surg.2016.10.012, indexed in Pubmed: 27894711.
21. Songun I, Putter H, Kranenbarg EMK, et al. Surgical treatment of gastric 
cancer: 15-year follow-up results of the randomised nationwide Dutch 
D1D2 trial. Lancet Oncol. 2010; 11(5): 439–449, doi: 10.1016/S1470-
-2045(10)70070-X, indexed in Pubmed: 20409751.
22. Katai H, Sasako M, Sano T, et al. The outcome of surgical treatment for 
gastric carcinoma in the elderly. Jpn J Clin Oncol. 1998; 28(2): 112–115, 
doi: 10.1093/jjco/28.2.112, indexed in Pubmed: 9544826.
23. Shuto K, Yamazaki M, Mori M, et al. [Partial Gastrectomy for Elderly 
Patients with Early-Stage Gastric Cancer]. Gan To Kagaku Ryoho. 2018; 
45(13): 1824–1826, indexed in Pubmed: 30692366.
24. Shinozuka T, Kanda M, Ito S, et al. D2 lymph node dissection confers 
little benefit on the overall survival of older patients with resectable 
gastric cancer: a propensity score-matching analysis of a multi-insti-
tutional dataset. Surg Today. 2020; 50(11): 1434–1442, doi: 10.1007/
s00595-020-02021-7, indexed in Pubmed: 32451713.
25. Suzuki S, Kanaji S, Matsuda Y, et al. Long-term impact of postopera-
tive pneumonia after curative gastrectomy for elderly gastric cancer 
patients. Ann Gastroenterol Surg. 2018; 2(1): 72–78, doi: 10.1002/
ags3.12037, indexed in Pubmed: 29863154.
26. Wang S, Xu L, Wang Q, et al. Postoperative complications and prognosis 
after radical gastrectomy for gastric cancer: a systematic review and 
meta-analysis of observational studies. World J Surg Oncol. 2019; 17(1): 
52, doi: 10.1186/s12957-019-1593-9, indexed in Pubmed: 30885211.
27. Kanda M, Ito S, Mochizuki Y, et al. Multi-institutional analysis of the 
prognostic significance of postoperative complications after curative 
resection for gastric cancer. Cancer Med. 2019; 8(11): 5194–5201, doi: 
10.1002/cam4.2439, indexed in Pubmed: 31353821.
28. Takeda J, Tanaka T, Koufuji K, et al. Gastric cancer surgery in patients 
aged at least 80 years old. Hepatogastroenterology. 1994; 41(6): 
516–520, indexed in Pubmed: 7721236.
29. Tanaka R, Lee SW, Imai Y, et al. Advantages of Laparoscopic Surgery 
for Gastric Cancer in Elderly Patients Aged Over 80 Years: A Propensity 
Score Matching Analysis. World J Surg. 2021 [Epub ahead of print], doi: 
10.1007/s00268-021-06157-6, indexed in Pubmed: 34019135.
30. Mikami R, Tanaka E, Murakami T, et al. The safety and feasibility of 
laparoscopic gastrectomy for gastric cancer in very elderly patients: 
short-and long-term outcomes. Surg Today. 2021; 51(2): 219–225, doi: 
10.1007/s00595-020-02078-4, indexed in Pubmed: 32676846.
31. Rausei S, Galli F, Milone M, et al. Laparoscopic distal gastrectomy in 
old-old patients: the first Western experience. Updates Surg. 2021 
[Epub ahead of print], doi: 10.1007/s13304-021-01063-x, indexed in 
Pubmed: 33900551.
32. Tanaka T, Suda K, Inaba K, et al. Impact of Frailty on Postoperative 
Outcomes for Laparoscopic Gastrectomy in Patients Older than 80 
Years. Ann Surg Oncol. 2019; 26(12): 4016–4026, doi: 10.1245/s10434-
019-07640-0, indexed in Pubmed: 31359279.
33. Drozd R. Kto powinien wybierać metodę leczenia operacyjnego – pa-
cjent czy lekarz? Chirurgia po Dyplomie. 2017; 2(12): 34–36.
34. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy 
with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus 
fluorouracil or capecitabine plus cisplatin and epirubicin for locally 
advanced, resectable gastric or gastro-oesophageal junction adenocar-
cinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393(10184): 
1948–1957, doi: 10.1016/s0140-6736(18)32557-1.
35. Lorenzen S, Pauligk C, Homann N, et al. Feasibility of perioperative 
chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with 
(FLOT) or without (FLO) docetaxel in elderly patients with locally ad-
vanced esophagogastric cancer. Br J Cancer. 2013; 108(3): 519–526, doi: 
10.1038/bjc.2012.588, indexed in Pubmed: 23322206.
36. van Hagen P, Hulshof MC, van Lanschot JJB, et al. CROSS Group. Pre-
operative chemoradiotherapy for esophageal or junctional cancer. N 
Engl J Med. 2012; 366(22): 2074–2084, doi: 10.1056/NEJMoa1112088, 
indexed in Pubmed: 22646630.
37. Slagter AE, Tudela B, van Amelsfoort RM, et al. Older versus younger 
adults with gastric cancer receiving perioperative treatment: Results 
from the CRITICS trial. Eur J Cancer. 2020; 130: 146–154, doi: 10.1016/j.
ejca.2020.02.008, indexed in Pubmed: 32208351.
38. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 
2016; 27(5): 38–49.
39. Schendel J, Jost E, Mah M, et al. Gastric cancer management in elderly 
patients: a population-based study of treatment patterns and outcomes 
in gastric cancer patients ≥ 75 years from Alberta, Canada. Am J Surg. 
2021; 221(4): 839–843, doi: 10.1016/j.amjsurg.2020.03.006, indexed in 
Pubmed: 32222273.
40. Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy 
versus chemotherapy alone for advanced gastric cancer with a single 
non-curable factor (REGATTA): a phase 3, randomised controlled trial. 
Lancet Oncol. 2016; 17(3): 309–318, doi: 10.1016/s1470-2045(15)00553-7.
41. Ueno D, Matsumoto H, Kubota H, et al. Prognostic factors for gastrectomy 
in elderly patients with gastric cancer. World J Surg Oncol. 2017; 15(1): 
59, doi: 10.1186/s12957-017-1131-6, indexed in Pubmed: 28284210.
42. Nie RC, Chen FP, Yuan SQ, et al. Evaluation of objective response, dise-
ase control and progression-free survival as surrogate end-points for 
overall survival in anti-programmed death-1 and anti-programmed 
death ligand 1 trials. Eur J Cancer. 2019; 106: 1–11, doi: 10.1016/j.
ejca.2018.10.011, indexed in Pubmed: 30453169.
43. Howlader N, Ries LAG, Mariotto AB, et al. Improved estimates of can-
cer-specific survival rates from population-based data. J Natl Cancer 
Inst. 2010; 102(20): 1584–1598, doi: 10.1093/jnci/djq366, indexed in 
Pubmed: 20937991.
